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BACKGROUND: Major depressive disorder (MDD) exhibits numerous clinical and molecular features that are
consistent with putative epigenetic misregulation. Despite growing interest in epigenetic studies of psychiatric
diseases, the methodologies guiding such studies have not been well deﬁned.
METHODS: We performed DNA modiﬁcation analysis in white blood cells from monozygotic twins discordant for
MDD, in brain prefrontal cortex, and germline (sperm) samples from affected individuals and control subjects (total
N 5 304) using 8.1K CpG island microarrays and ﬁne mapping. In addition to the traditional locus-by-locus
comparisons, we explored the potential of new analytical approaches in epigenomic studies.
RESULTS: In the microarray experiment, we detected a number of nominally signiﬁcant DNA modiﬁcation
differences in MDD and validated selected targets using bisulﬁte pyrosequencing. Some MDD epigenetic changes,
however, overlapped across brain, blood, and sperm more often than expected by chance. We also demonstrated
that stratiﬁcation for disease severity and age may increase the statistical power of epimutation detection. Finally, a
series of new analytical approaches, such as DNA modiﬁcation networks and machine-learning algorithms using
binary and quantitative depression phenotypes, provided additional insights on the epigenetic contributions to MDD.
CONCLUSIONS: Mapping epigenetic differences in MDD (and other psychiatric diseases) is a complex task.
However, combining traditional and innovative analytical strategies may lead to identiﬁcation of disease-speciﬁc
etiopathogenic epimutations.
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Biohttp://dx.doi.org/10.1016/j.biopsych.2014.06.016Major depressive disorder (MDD) is a psychiatric disease
characterized by an all-encompassing low mood accompa-
nied by low self-esteem, loss of interest or pleasure in normally
enjoyable activities, and a variety of other associated symp-
toms (1). MDD affects one in seven individuals (2) and has
been projected to become the second leading cause of
disability worldwide by 2020 (3).
A meta-analysis of twin studies on MDD estimated herit-
ability at 37% (4), which is consistent with a recent large
epidemiologic study (5). This signiﬁcant heritability provided a
basis for molecular genetic studies; however, identiﬁcation
of speciﬁc MDD risk genes has proven difﬁcult. A recent
genome-wide association study with .18,000 subjects in the
discovery phase did not detect any genome-wide signiﬁcant
single nucleotide polymorphisms (SNPs). The study followed
up on the top 554 SNPs (p , .0001) in an independent set of
.57,000 subjects but failed to replicate any of the SNPs at
genome-wide signiﬁcance (6).6 & 2015 Society of Biological Psychiatry. Published by Elsevier Inc.
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OpMDD exhibits numerous non-Mendelian features that can
be reviewed from an epigenetic perspective (7). Such features
include partial heritability, discordance of monozygotic (MZ)
twins, sexual dimorphism (8,9), disease onset following major
hormonal changes (e.g., postpartum depression) (10), and
ﬂuctuating course of disease (11). Epigenetics refers to the
regulation of various genomic functions that are controlled by
heritable but reversible chemical modiﬁcations of DNA and
histones (12). Environmental factors such as stress, diet, and
drugs can alter the epigenetic proﬁle (13,14). Even in the
absence of environmental exposures, stochastic epigenetic
changes may inﬂuence phenotypic outcomes (15). Further-
more, there is increasing evidence that epigenetic factors, in
addition to DNA sequences, account for heritability (16,17). In
short, we postulate that inherited and acquired epigenetic
misregulation may play an etiological role in MDD (7).
In this study, we attempted to identify MDD speciﬁc epige-
netic changes using a series of experimental and analyticall ISSN: 0006-3223
RY ON PAGE
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Psychiatryapproaches, from traditional locus-by-locus comparisons to new
systems biology-based strategies, such as epigenomic networks
and machine-learning based classiﬁcation.METHODS AND MATERIALS
Samples
Tissue samples were collected from individuals diagnosed with
MDD and from matched control subjects. Inclusion criteria
involved patients between the ages of 18 and 75 diagnosed
with MDD according to DSM-IV criteria. Individuals with a prior
history of other mental illnesses, addiction and substance abuse,
or a family history (ﬁrst-degree relatives) of schizophrenia were
excluded from the study. The 100 discordant MZ twin samples
consisted of peripheral blood DNA from 40 pairs of MZ twins
from Australia, 46 pairs from The Netherlands, and 14 pairs from
the United Kingdom (for detailed description, see Supplement 1).
Seventy-one prefrontal cortex samples were received from the
Stanley Medical Research Institute (SMRI) and Quebec Suicide
Brain Bank (QSBB). Thirty-three sperm samples from bipolar
disorder patients, a disease that may be etiologically related to
MDD (18,19), and control subjects were obtained from an
ongoing study at the Centre for Addiction and Mental Health
(Toronto, Ontario, Canada). More information on the samples can
be found in Table S1 in Supplement 1.
Microarray Experiment
The unmodiﬁed DNA fraction was enriched using modiﬁed
cytosine (modC)-sensitive restriction enzymes, which collec-
tively interrogate 5-methylcytosine and 5-hydroxymethyl-
cytosine (20) (it is assumed that 5-carboxylcytosine and 5-
formylcytosine are rare and unlikely to signiﬁcantly contribute
to the estimates of the modiﬁed/unmodiﬁed cytosines). Three
aliquots of 250 ng of genomic DNA were digested individually
with HpaII, HinP1I, and HpyCH4IV and pooled together after
digestion was completed. For the twin samples, 500 ng of
genomic DNA was digested using only HpaII. All other steps
were identical to those described in our published protocol
(21). The microarray experiment was conducted using a
common reference pool design. The enriched polymerase
chain reaction products were labeled with Cy3 for the refer-
ence and Cy5 for the sample hybridized onto 8.1K human CpG
island microarrays (22,23). A detailed description of the
bioinformatic methods can be found in Supplement 1.
Bisulﬁte modiﬁcation and pyrosequencing-based ﬁne map-
ping of modC was performed using a standard protocol (24).
The primers for the bisulﬁte polymerase chain reaction were
designed using either the MethPrimer (25) or the Pyrosequenc-
ing Assay Design Software v1.0.6 (Qiagen, Valencia, California)
(Table S2 in Supplement 1). For pyrosequencing, Gold Q96
Reagents and Pyromark Q24 were used (Qiagen).
Ethics Statement
Centre for Addiction and Mental Health Research Ethics Board
granted approval to protocol # 024/2005-01 entitled “Molec-
ular epigenetic studies of major depression.” All experiments
were performed in accordance with relevant guidelines and
regulations.Biological PsyRESULTS
Locus-Speciﬁc Analysis of DNA Modiﬁcation in the
Brain, White Blood Cells, and the Germline
In the human brain samples from the SMRI, a locus-by-locus
comparison between MDD or MDD with psychosis (MDD 1
Psy) and control subjects using analysis of variance revealed
40 differentially modiﬁed loci (nominal p 5 4 3 1025 2 .01;
Table S4 in Supplement 1); 22 loci showed differential
modiﬁcation between MDD and control subjects, and 18 loci
showed differential modiﬁcation between MDD 1 Psy and
control subjects (Tukey’s honestly signiﬁcant difference,
p , .05). Eight loci were differentially modiﬁed for both MDD
and MDD 1 Psy compared with control subjects. One gene,
FOXD3, was previously implicated in MDD (26). The analysis of
the brain samples from the QSBB revealed 35 loci with
differential modiﬁcation (nominal p 5 5 3 1024 2 .01). In
white blood cells (WBCs) from MZ twins discordant for MDD,
we identiﬁed 44 loci with nominal p 5 9 3 1025 2 .01. Lastly,
in the sperm samples from individuals affected with bipolar
disorder and control subjects, we found 34 loci (nominal
p 5 6 3 1024 2 .01), one of which had already been
implicated in bipolar disorder (SMAD3) (27).
We did not ﬁnd signiﬁcant overlaps between any of the
samples tested above. However, we found a statistically
signiﬁcant number of overlapping loci between our study
and a previously published epigenome-wide study using the
same SMRI brain samples but different enrichment technique
and platform (at nominal p , .05 for both studies) (28). We
performed permutation analysis and found that our microarray
probes that were either directly on or nearest neighbors
(median distance 5 12 kb) to the gene of interest were
overrepresented than by chance (n 5 14; permuted p 5 .04;
Table S5 in Supplement 1). Even when the parameters were
made more stringent to only include microarray probes that
were either directly on or within a short distance away (,10 kb
or ,5 kb) from the gene of interest, we still found a signiﬁcant
number of overlaps between the two studies (n 5 12 for both;
p 5 .03 and p 5 .02, respectively).
None of the detected loci survived correction for multiple
testing, although 13 loci with nominal p , .05 overlapped with
either the SMRI or the QSBB brain samples and the WBC
samples of the MDD twins. Among the 13 loci, probes for
LRRC41 and LIN28A contained regulatory sequences, nuclear
factor-κB transcription factor binding site, and a predicted
insulator CTCF binding site, with modC sensitive sites (Figure 1)
(29). These two loci, plus three different types of repetitive
elements (LINE-1, NBL-2, and D4Z4) as proxies for global
modiﬁcation changes (30), were ﬁnely mapped using bisulﬁte
pyrosequencing. A total of 29 CpG sites (11, 4, 3, 6, and ﬁve
CpG sites for LRRC41, LIN28A, LINE-1, NBL-2, and D4Z4,
respectively) were interrogated from the two unique DNA loci
and three repetitive DNA elements.
Bisulﬁte pyrosequencing revealed that modC density at
LIN28A was different in the SMRI MDD 1 Psy samples com-
pared with control subjects (Mann-Whitney test, p 5 .01).
While the pooled MDD samples (MDD and MDD 1 Psy) also
showed signiﬁcant differences (p 5 .01), MDD alone versus
control subjects did not reach signiﬁcance (p 5 .08), and the
same was detected in the QSBB samples (p 5 .77). We alsochiatry February 1, 2015; 77:246–255 www.sobp.org/journal 247
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Figure 1. Location of ﬁne mapping by bisulﬁte pyrosequencing and transcription factor binding sites for LRRC41 and LIN28A in the prefrontal cortex of
postmortem brains. Both the LRRC41 (A) and LIN28A (B) loci contain regulatory sites within the probe sequence (red font). The green CpG sites indicate
regions that were ﬁnely mapped using bisulﬁte pyrosequencing. Mean LRRC41 and LIN28A modiﬁed cytosine (modC) densities were found to be differentially
modiﬁed between major depressive disorder (MDD) patients and control subjects in the Quebec Suicide Brain Bank and Stanley Medical Research Institute
samples, respectively. LRRC41 in the Quebec Suicide Brain Bank samples showed a mean modiﬁcation difference 6 SD (ΔmodC) of 1.3% 6 1.6% between
control subjects and MDD. LIN26A in the Stanley Medical Research Institute control subjects compared with depression with psychosis showed ΔmodC of
6.8% 6 10.8%, while control subjects vs. MDD alone was 4.3% 6 12.1%. *Speciﬁc CpG positions that were found to be signiﬁcantly different between the
affected and the unaffected individuals. The dark yellow boxes on the right show the average modiﬁcation densities (Ave % modC) across all sites. C, control
subjects; D, depression (MDD); P, depression with psychosis.
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Psychiatryobserved signiﬁcant differences in LRRC41 in the QSBB
samples (p 5 .004) but not in the SMRI brain samples
(Kruskal-Wallis test, p 5 .10). Age, sex, and antipsychotic
use did not show an association with the modC status of
LIN28A or LRRC41. Consistent with other psychiatric diseases
(31,32), the average density of modC was similar in MDD
patients and control subjects across the three repetitive DNA
elements tested (Table S6 in Supplement 1).
Next, we attempted to understand why the conventional
mean difference-based analysis uncovered only minor epige-
netic changes in MDD and investigated two confounding
factors: putative MDD heterogeneity and age effects.
Effects of the Degree of MZ Twin Discordance and
Age-Dependent Heteroscedasticity of DNA
Modiﬁcation
Despite the obvious advantages of discordant MZ twin design
in epigenomic studies, the unaffected co-twins are at a higher
risk for MDD than the general population (33,34); therefore,
they may carry some epigenetic risk factors, which reduces
the power of detection of disease-speciﬁc epigenetic differ-
ences. To test this hypothesis, we analyzed subgroups of MZ
twins with differing degrees of discordance for MDD. We
utilized twin discordance information derived from the person-
ality questionnaires, reported number of episodes, and inter-
views of the MZ twins to separate the most discordant from
least discordant (35). The severity of disease discordance
between the MZ twins indeed played a role; when we
performed t tests using the 10 most discordant MZ pairs, we
found 165 signiﬁcant loci with nominal p , .05 but only 81 in248 Biological Psychiatry February 1, 2015; 77:246–255 www.sobp.orthe 10 least discordant pairs (Fisher’s exact test, p 5 3.3 3
1028). The two middle groups of discordant twins showed an
intermediate number of statistically signiﬁcant differences
(Figure 2A).
Another factor that may have compromised identiﬁcation of
signiﬁcant epigenetic differences was age-dependent incon-
sistency in the variance of modC. This phenomenon, generally
known as heteroscedasticity, occurs when subsets of the
samples have different degrees of variability. In the Australian
MDD twins, we found 489 loci that exhibited changing
variance with age in both the affected and the unaffected
co-twins (Harrison-McCabe test, false discovery rate, q , .05)
(Figure 2B). The majority (76%) of the heteroscedastic loci
showed increasing modC variance with age.
To verify if this phenomenon had an impact on statistical
power, we performed t tests only on the heteroscedastic loci
after separating the dataset into two groups by age: the
younger half (32.1 6 4.6 years; mean age 6 SD) and the
older half (50.3 6 8.5 years). We found more differing loci
between the affected and the unaffected twins in the younger
group compared with the older group (20 and 9, respectively;
Fisher’s exact test, p 5 .004), indicating that age-dependent
heteroscedasticity reduces statistical power (Figure 2C).
MDD DNA Modiﬁcation Differences Detected in More
Than One Tissue
To identify MDD epigenetic features that were common across
tissues, we analyzed the largest modC differences (.1.64 SD
from the mean) in the brain, WBC, and sperm of diseased
individuals compared with control subjects. The number of locig/journal
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Figure 2. Effects of major depressive disorder twin discordance and age on the number of DNA modiﬁcation differences in white blood cells. (A) Each data
point represents a group of 20 twins (10 sets), from the most discordant twins on the left to the least discordant twins on the right. The number of loci found to
be signiﬁcant using t test decreases as the twins become less discordant. Fisher’s exact test showed that the number of loci detected as signiﬁcant were
higher in the more discordant twin groups compared with least discordant group. (B) Each line represents a linearly ﬁtted line of the absolute value (Abs) of the
residuals of a heteroscedastic locus (Harrison-McCabe test, false discovery rate q , .001). The positive slope (red line) indicates increasing variance with age
and the negative slope (blue line) indicates the opposite. (C) The two age groups represent the youngest half and the oldest half of the Australian twins. The
number of loci found to be signiﬁcant is consistently lower in the old group compared with the young group.
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Psychiatryexhibiting higher degrees of DNA modiﬁcation in MDD patients
compared with control subjects was disproportionate to the
number of loci exhibiting lower degrees of DNA modiﬁcation
and vice versa. Hypermethylated loci dominated in the WBC of
affected MDD twins (n 5 408 of 571; p 5 2.2 3 10216), while
the brain and the sperm showed higher proportions of hypo-
methylated regions in MDD patients compared with control
subjects (n 5 437 of 803, p 5 4.5 3 1023; and n 5 405 of 645,
p 5 6.8 3 1022, respectively). The asymmetry in the direction
of epigenetic changes in the brain and sperm compared with
the WBC likely reﬂects tissue-speciﬁc epigenetic events,
including differential impact of psychotropic medications, dis-
ease compensatory mechanisms, and other factors.
We found 110 common genes and regions between the
brain cortex and sperm (binomial test p 5 8.0 3 1028), 81 loci
overlapped between the WBC and sperm samples (p 5 1.1 3
1026), and 58 loci were shared between the brain cortex and
WBC samples (p 5 .4) (Figure 3A). Fourteen loci were common
in all three tissues (p 5 2.5 3 1024), among which NLGN1 was
previously implicated in MDD (36). Gene Ontology (GO)
enrichment analysis of overlapping loci across different tissues
showed enrichment of terms related to cell proliferation on
forebrain, fat cell differentiation, and glutamate signaling path-
way, among others (Table S7 in Supplement 1).
Epigenetic Outliers Are More Prevalent in MDD
Patients
We deﬁned samples as epigenetic outliers if the modC for a
given locus deviated substantially from the average modC value
of the overall sample. The outliers were categorized into three
groups: gene coding, intergenic, and those mapping to
regions of known copy number variants, which may generateBiological Psyfalse evidence for epigenetic outliers (Figure 4). In the gene
coding regions, we found 3123 outliers in the affected MZ twins
and 2747 in the unaffected co-twins (Fisher’s exact test, p 5 2.2
3 10212). In the intergenic regions, there were 1576 outliers in
the affected twins and 1444 in the unaffected co-twins (Fisher’s
exact test, p 5 3 3 1024). No signiﬁcant difference was
detected in the number of outliers between MDD twins
(n 5 42) and co-twins (n 5 39) in the copy number variant
regions. The outliers were not driven by a small subset of
individuals; rather, they were the products of small contributions
from numerous individuals over many loci. On average, each
affected and unaffected co-twin contributed 15.3 6 26.8 and
14.8 6 27.2 (mean 6 SD) outliers, respectively.
Epigenomic Network Analysis
We performed two types of network analysis. The ﬁrst was a
weighted correlation network utilizing continuous personality
traits associated with MDD. Some personality dimensions are
good predictors of MDD risk and prognosis (37–39), and we
applied these continuous phenotypes in the network analysis
(40). This approach avoids the loss of power that stems from
dichotomizing individuals into affected and control groups, as
well as excessive correction for multiple comparisons (41,42).
The scales of the personality tests administered at the
twin registries were not directly comparable, so each twin
group (Dutch, United Kingdom, and Australian) was analyzed
separately.
The network analysis revealed modules (groups of loci
correlating for DNA modiﬁcation) that were related to personality
dimensions (neuroticism, extraversion, or anxiety) in all the
twin groups. In the Dutch twins, we identiﬁed 33 modules, 2 of
which correlated with the personality dimensions neuroticismchiatry February 1, 2015; 77:246–255 www.sobp.org/journal 249
Figure 3. DNA modiﬁcation across different tissue
types and partial correlation network. The gray bars
below the ideogram show the chromosomal mapping
of the probe covered by the CpG island microarray.
(A) The different tracks represent different tissue
types where light green 5 cortex, yellow 5 white
blood cells, and orange 5 sperm. The black bars in
the tracks indicate loci with differential modiﬁed
cytosine (modC) across different tissue types, as
deﬁned by modC differences that are more than 1.64
SD away from the mean DNA modiﬁcation differences
between major depressive disorder patients and
control subjects. The black bars that are overlapping
across the tracks represent loci that are differentially
modiﬁed across tissues. (B) Each bar represents a
locus that serves as a node in the partial correlation
network. The height of the bars represents the density
of connections in the network (i.e., number of edges
to that node). Many of the loci that show differential
modC across different tissues also show a high
number of edges. (C) The lines show interactions
between nodes from the partial correlation network.
The black lines show nodes that are interacting with
the differential modC across different tissues and the
gray lines show all other interactions. This ﬁgure was
created using Circos (62).
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Psychiatry(p = 3.0 3 1024 and p = .01 for the ﬁrst and second modules,
respectively) and extraversion (p = 6.0 3 1024 and p = .03). GO
analysis of the ﬁrst module showed enrichment of terms related
to postsynaptic membrane, synapse, and postsynaptic density,
while the second module was related to lipid metabolic process,
glycolipid metabolic process, and response to insulin stimulus
(Table S7 in Supplement 1). In the United Kingdom twins, 15
modules were identiﬁed, 1 of which correlated with neuroticism
and 2 others correlated with anxiety (p 5 .004, p 5 .01, and
p 5 .03, respectively). The GO terms for these modules were
related to heart development, methionine metabolic process, and
forebrain formation, respectively. In the Australian twins, 1
module (out of 17) showed a signiﬁcant correlation with extra-
version (p 5 .03) and enrichment of terms related to Rho
guanosine triphosphate (GTP)ase binding, one of a number of
critical processes in neuronal migration.
The second network-based approach was partial correla-
tion analysis, which eliminates indirect relationships (i.e.,
correlation between two variables that is mediated by a third
variable) to reveal true interactions between loci (43). The
partial correlation network revealed differences in the network
property (Figure 5); affected MZ twins had a larger number of
edges compared with their unaffected twins (n 5 1453 and
n 5 1196, respectively), despite having similar number of
nodes (n 5 691 and n 5 686, respectively). We also observed
that a signiﬁcant number of nodes, in both the affected and
normal networks, overlapped with the differentially modiﬁed
loci in the brain cortex and the sperm (see MDD DNA250 Biological Psychiatry February 1, 2015; 77:246–255 www.sobp.orModiﬁcation Differences Detected in More Than One Tissue).
Of the 110 overlaps identiﬁed between the cerebral cortex and
the sperm, we saw 34 overlapping nodes in the network of
affected individuals and 27 in the control network (binomial
test, p 5 2.2 3 10216 and p 5 3.0 3 10211, respectively).
Many of the overlapping nodes were common in both the
affected (25 of 34 nodes) and the normal network (25 of 27
nodes) (Table S8 in Supplement 1). Between 691 nodes from
the affected network and 686 nodes from the normal network,
there were 308 common nodes, which suggest commonality
between the affected individuals and the control subjects. GO
enrichment analysis of the common nodes showed enrich-
ment of terms related to development and homeostasis (Table
S7 in Supplement 1). Lastly, we found that the differentially
modiﬁed loci between MDD patients and control subjects may
act as hubs (i.e., nodes with high number of edges) in the
network (Figure 3B,C). When we investigated the top 100
hubs, we found that 14 hubs overlapped with loci that were
previously identiﬁed to be modiﬁed across multiple tissues
(binomial test, p 5 1.9 3 10213), more speciﬁcally, the ones
that were overlapping between the cortex and the sperm.
Discriminant Analysis of MDD Patients and Control
Subjects
The discriminant analysis showed that most samples could be
classiﬁed with high discrimination power when analyzed within
the same tissue type (Table S9 in Supplement 1). The affected
and control samples were divided into two groups, learning org/journal
Figure 4. Epigenetic outliers by chromosomal
coordinates in white blood cells. The gray bars below
the ideogram show the chromosomal mapping of the
probe covered by the CpG island microarray. (A) Red
and blue bars represent normalized numbers of out-
liers, calculated by taking the difference in the number
of outliers between major depressive disorder pa-
tients and control subjects, for each locus. Red bars
show loci where there are more outliers from the
affected individuals compared with control subjects,
while the blue bars show the opposite. There are
more red bars than blue, indicating that DNA mod-
iﬁcation outliers are more prevalent in major depres-
sive disorder patients. (B) The plot shows the
absolute number of outliers (maximum 10) for each
locus from either the affected (red) or the control
(blue) individuals. This ﬁgure was created using
Circos (62).
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Psychiatrytesting, using stratiﬁed random sampling. The informative
array probes that could distinguish MDD patients and control
subjects (Table S3 in Supplement 1) were selected from the
learning group using a correlation-based feature subset
selection.
Using the informative loci (attributes) selected from the
learning group in the combined SMRI and QSBB brain
samples, we were able to correctly classify 76% to 81% of
the individuals in the testing set according to their phenotype
with receiver operating characteristic (ROC) areas of .77 to .82.
The blood samples, on the other hand, showed conﬂicting
results. In the analysis using all the twin samples (Australian,
United Kingdom, and Dutch), we were unable to discriminate
affected individuals from control subjects. However, when the
samples were separated into European and Australian twins
and treated independently, we were able to obtain ROC of .62
to .84 for the European twin samples. However, the model
based on the Australian twins reverse classiﬁed cases and
control subjects (ROC of .24 to .46).
Finally, we evaluated the cross-tissue classiﬁcation of the
model (i.e., attributes selected from sperm and tested on
cortex). If an organism-wide epimutation is present, the
algorithm should be able to correctly classify the phenotypes
of the testing set, despite the presence of tissue-speciﬁc modC
patterns. Interestingly, models created using attributes
selected from the bipolar disorder germline samples were able
to classify cortex samples from the SMRI and QSBB; the ROC
ranged from .52 to .76. The results improved when only theBiological PsyQSBB samples were classiﬁed; 73% to 75% of the cases and
control subjects were sorted correctly (ROC of .78 to .95). One
of the informative probes represented EMX2, a gene that was
previously implicated in MDD (44).DISCUSSION
Overall, our locus-by-locus analysis yielded a number of
modest modC differences across multiple loci, none of which
survived correction for multiple testing. Veriﬁcation by bisulﬁte
sequencing conﬁrmed signiﬁcant modC differences, which
showed effect sizes that were comparable with previous
epigenetic studies of psychiatric disorders (28,45). Some of
our detected genes have been previously implicated in MDD
(26,36,44). In addition, we identiﬁed a signiﬁcant overlap of
differentially modiﬁed genes between this and another epige-
netic study of MDD (28). This is quite remarkable considering
the numerous differences between the two studies (such as
microarray platforms, target probes, enrichment strategies,
and data analyses) and could serve as an independent
validation of modC in MDD using the same tissue but different
technical platforms.
Our study shows that the reasons why the locus-speciﬁc
analysis has not resulted in signiﬁcant markers for MDD may
include: 1) putative MDD heterogeneity; 2) excessively con-
servative correction for multiple testing; and 3) age-dependent
increase in variation of modC, which we referred to as age-
dependent heteroscedasticity.chiatry February 1, 2015; 77:246–255 www.sobp.org/journal 251
Normal networkAffected network
Figure 5. Partial correlation network analysis. Each node represents a microarray probe and the edges represent the interactions between the nodes.
Partial correlation network analysis using white blood cells from the monozygotic twins revealed that the affected individuals and control subjects have
different methylome network properties. Major depressive disorder patients showed a higher number of edges compared with normal individuals (1453 vs.
1196), despite containing a similar number of nodes (691 vs. 686) in the network.
DNA Modiﬁcation Study
Biological
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ies can utilize an arsenal of analytical approaches much larger
than in DNA studies. For example, we performed replication of
brain ﬁndings using non-brain tissues: WBC of MZ twins and
germline of bipolar disorder patients. We showed that differ-
entially modiﬁed regions exhibited a highly signiﬁcant number
of overlaps across the three tested tissues (binomial test,
p 5 8.0 3 1028 to p 5 2.5 3 1024). We also sought
epigenetic outliers—rare epigenetic differences that are
detected only in one or several individuals from the entire
sample. The number of outliers in the group of MDD patients
(n 5 4741) signiﬁcantly exceeded the number of outliers in the
control subjects (n 5 4230). A recently published study found
higher variance of DNA modiﬁcation in the group of affected
MDD twins compared with the unaffected co-twins (46), which
is consistent with our current observation. Our ﬁnding adds to
the observation that variation of modiﬁcation, rather than the
differences in mean, plays a role in disease (47).
To fully utilize available phenotypic information, we used
network analysis in conjunction with quantitative trait data. We
were able to extract new information by comparing changes in
modC patterns of co-regulated genes with continuous MDD
traits of neuroticism and extraversion (37,48,49). We identiﬁed
enrichment of pathways related to synaptic and lipid metabolic
processes that correlated with neuroticism and extraversion
and a methionine metabolic process that correlated with
anxiety. Also, the synaptic pathway consists of genes related
to glutamate receptors and aberrant metabolism, both of
which have been implicated in MDD (50,51). Furthermore,
the methionine metabolic pathway has been similarly impli-
cated in that supplementation of a methyl group donor,252 Biological Psychiatry February 1, 2015; 77:246–255 www.sobp.orS-adenosylmethionine, has been suggested as a treatment
for MDD (52). We also found that pathways related to heart
development, forebrain anterior/posterior pattern formation,
and Rho GTPase binding may also play a role in personality
traits such as neuroticism, extraversion, and anxiety. Rho
GTPase activating protein 6 was found to be differentially
expressed in suicide completers (53) and disruption of path-
ways involving Rho GTPase activation has been associated
with MDD and bipolar disorder (54,55).
Another type of network, the partial correlation network,
showed that many of the nodes were shared between the
networks of MDD and control individuals. The shared nodes
overlapped with differentially modiﬁed loci across different
tissues and played an important role as hubs in the network.
Further analysis showed that the nodes were preferentially
enriched for loci with high coefﬁcients of variation. Therefore,
our current observation suggests that differential modC in MDD
occurs in more variable regions of the genome that may be
related to development and homeostasis.
Finally, we used a combination of small modC differences to
classify the phenotypes using machine-learning algorithms. In
most cases, we were able to accurately classify the samples
into the correct phenotypes within the same tissue type.
Furthermore, we were able to use attributes selected from
the germline samples to correctly classify up to 75% of the
postmortem brain samples of MDD patients. These ﬁndings
may point to a heritable epigenetic basis for MDD and bipolar
disorder, although they may also reﬂect epigenetic effects of
treatment or some other disease-related phenomenon.
In other cases, discriminant analysis showed conﬂicting
results. Although we were able to correctly classify 70% tog/journal
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Psychiatry81% of the European twins, we were unable to discriminate the
Australian twins. One likely explanation for the different results
may be related to environmental variation. In fact, twin studies
have detected that the inﬂuence of the shared environment was
substantially greater in Dutch MZ twins as compared with
Australian MZ twins (in the old cohort, 46% and 10%, respec-
tively), and the different outcomes were attributed to the differ-
ences in population densities (56,57). Accordingly, we might
expect the following: the lower the contribution of shared
environment, the higher the degree of epigenetic variation.
For WBC-based study, it is possible that blood cell count
differences may simulate epigenetic false positives (17). How-
ever, it is unlikely that our ﬁndings are epigenetic artifacts.
Using gene expression data as a proxy for DNA modiﬁcation,
there were 1150 genes uniquely expressed in either B cells,
CD41 T cells, CD81 T cells, lymphocytes, or granulocytes
(58); only 2.15% of these genes were represented in the 8.1K
human CpG island microarray.
Some of the epigenetic differences detected in MDD
patients compared with control subjects may, in fact, be
induced by the treatment (59–61). We cannot exclude the
possibility that the surprisingly successful classiﬁcation of
brain samples using germline modC proﬁles may reﬂect
organism-wide treatment effects. Such hypotheses may open
new and important research avenues: how different medica-
tions affect the germline, how drug-induced epigenetic
changes can be transmitted to the next generation, and how
such changes may affect the health of the offspring.
We have explored numerous aspects of how DNA modiﬁca-
tion may be involved in MDD, identiﬁed several areas that need
further consideration, and introduced a number of new methods.
There are several limitations in this study, which should be
considered and addressed in the future. Enrichment techniques
should distinguish various types of cytosines (unmodiﬁed
cytosine, 5-methylcytosine, 5-hydroxymethylcytosine, 5-carbox-
ylcytosine, and 5-formylcytosine) and these multiple layers of
epigenome should be interrogated using high-resolution tech-
niques and platforms covering the entire genome. With increas-
ing numbers of interrogated genes and loci, larger samples will
be necessary to deal with severe penalties for multiple testing.
Samples with balanced male to female ratio may help to
uncover sex-speciﬁc predisposition to MDD. The issue of
cellular heterogeneity remains open in epigenomic studies of
brain diseases. Separation of neuronal from nonneuronal brain
cells is only a partial solution, as it cannot distinguish different
types of neurons and different types of nonneuronal cells.
Despite the complexities inherent in human studies, this
work demonstrates that application of new analytical
approaches may signiﬁcantly advance the ﬁeld of psychiatric
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